Prolonged temozolomide for treatment of glioblastoma: Preliminary clinical results and prognostic value of p53 overexpression

Journal of Neuro-Oncology

Volumn 106, Issue 1, 2012, Pages 127-133

  Malkoun, Nadia ^a   Chargari, Cyrus ^b   Forest, Fabien ^c   Fotso, Marie Jeannette ^c   Cartier, Lysian ^a   Auberdiac, Pierre ^a   Thorin, Julie ^a   Pacaut, Cécile ^a   Peoc'H, Michel ^c   Nuti, Christophe ^c   Schmitt, Thierry ^a   Magné, Nicolas ^a  

^a Institut de Cancerologie de la Loire   (France)

^b University of Paris Descartes   (France)

^c UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

Author keywords

Chemoradiotherapy; EGFR; Glioblastoma; p53; Prognostic factors; Prolonged adjuvant therapy; Temozolomide

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53; TEMOZOLOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CELL PROLIFERATION; CHEMORADIOTHERAPY; CHROMOSOME 1P; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEASIBILITY STUDY; FEMALE; GENE DELETION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; INFECTION; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MOLECULAR GENETICS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PNEUMOCYSTOSIS; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 83055194642     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0643-0     Document Type: Article

References (16)

1. R Stupp WP Mason MJ van den Bent M Weller B Fisher MJ Taphoorn, et al. 2005 Radiotherapy plus concomitant and adjuvant TMZ for GBM N Engl J Med 352 987 996 15758009 10.1056/NEJMoa043330 1:CAS:528:DC%2BD2MXit1Wksbk%3D (Pubitemid 40349501)
2. RO Mirimanoff 2006 The evolution of chemoradiation for glioblastoma: a modern success story Curr Oncol Rep 8 50 53 16464403 10.1007/s11912-006-0009-5
3. M Weller J Felsberg C Hartmann, et al. 2009 Molecular predictors of progression-free and overall survival in patients with newly diagnosed GBM: a prospective translational study of the German Glioma Network J Clin Oncol 27 5743 5750 19805672 10.1200/JCO.2009.23.0805 1:CAS:528:DC%2BC3cXhtVWisbg%3D
4. S Haberer A Assouline JJ Mazeron 2010 Normal tissue tolerance to external beam radiation therapy: brain and hypophysis Cancer Radiother 14 263 268 20488744 10.1016/j.canrad.2010.02.005 1:STN:280:DC%2BC3cjkvF2rsg%3D%3D
5. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007) WHO classification of tumours of the central nervous system. IARC, Lyon
6. PF Ambros IM Ambros 2001 Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines Med Pediatr Oncol 37 492 504 11745887 10.1002/mpo.1242 1:STN:280: DC%2BD3MnpslSnug%3D%3D (Pubitemid 33101388)
7. WP Mason RD Maestro D Eisenstat P Forsyth D Fulton N Laperriere, et al. 2007 Canadian recommendations for the treatment of glioblastoma multiforme Curr Oncol 14 110 117 17593983 10.3747/co.2007.119 1:STN:280:DC%2BD2sznsl2jtQ%3D%3D (Pubitemid 47204238)
8. P Hau D Koch T Hundsberger E Marg B Bauer R Rudolph, et al. 2007 Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma Neurology 68 688 690 17325277 10.1212/01.wnl.0000255937.27012.ee 1:CAS:528:DC%2BD2sXhvFWrs7c%3D (Pubitemid 46667817)
9. J Baurain T Boterberg D Devriendt F Hammouch G Cosnard N Whenham PM Clement C Mitine L Renard 2010 Interim analysis of the randomized PATSGO trial evaluating the prolongation of adjuvant temozolomide in newly diagnosed glioblastoma patients J Clin Oncol 28 204 (abstract)
10. IF Pollack SD Finkelstein J Burnham EJ Holmes RL Hamilton AJ Yates JL Finlay R Sposto Children's Cancer Group 2001 Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort Cancer Res 61 7404 7407 11606370 1:CAS:528:DC%2BD3MXnvFShs7o%3D (Pubitemid 32995024)
11. M Miyagami S Nakamura 1998 Evaluation of p53 protein expression and proliferative potential based on the MIB-1 positive index in astrocytic gliomas Neuropathology 18 154 161 10.1111/j.1440-1789.1998.tb00094.x (Pubitemid 28321132)
12. M Miyagami M Tazoe S Nakamura 1998 Expression of vascular endothelial growth factor and p53 protein in association with neovascularization in human malignant gliomas Brain Tumor Pathol 15 95 100 10328546 10.1007/BF02478890 1:STN:280:DyaK1M3lvFSqug%3D%3D
13. EM Hendriksen PN Span J Schuuring JP Peters FC Sweep AJ van der Kogel J Bussink 2009 Angiogenesis, hypoxia and VEGF expression during tumour growth in a human xenograft tumour model Microvasc Res 77 96 103 19118564 10.1016/j.mvr.2008.11.002 1:CAS:528:DC%2BD1MXisFWns78%3D
14. Kang HC, Kim CY, Han JH, Choe GY, Kim JH, Kim JH, Kim IA (2011) Pseudoprogression in patients with malignant gliomas treated with concurrent TMZ and radiotherapy: potential role of p53. J Neurooncol 102:157-162
15. EC Burton KR Lamborn P Forsyth, et al. 2002 Aberrant p53, mdm2, and proliferation differ in GBMs from long-term compared with typical survivors Clin Cancer Res 8 180 187 11801556 1:CAS:528:DC%2BD38XhsVKmu7w%3D (Pubitemid 34101475)
16. D Bocangel S Sengupta S Mitra KK Bhakat 2009 p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor Anticancer Res 29 3741 3750 19846904 1:CAS:528:DC%2BD1MXhsVOlt7vP